BRD4 Ligand
- 1
-
Nrf2 activator-1
0 ImagesNrf2 activator-1 is a potent activator of NF-E2 related factor 2 (Nrf2). Nrf2 activator-1 has the potential for the research of COPD and other respiratory diseases, including asthma, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS) and pulmonary fibrosis (extracted from patent WO2018109647A1).
-
Desmethyl-QCA276
0 ImagesSynonyms: PROTAC BRD4-binding moiety 4Desmethyl-QCA276 (PROTAC BRD4-binding moiety 4), the QCA276-based moiety, binds to cereblon ligand via a linker to form PROTAC to degrade BET. QCA276 is a BET inhibitor with an IC50 of 10 nM, and with a Ki of 2.3 nM. Desmethyl-QCA276 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
-
BRD4/FKBP12 ligand 2
0 ImagesCat. No.: HY-176476BRD4/FKBP12 ligand 2 is a heterobifunctional BRD4 and FKBP12 (Kd of 1.0 nM) ligand. BRD4/FKBP12 ligand 2 has positive cooperativity in BRD4 binding when pre-bound to FKBP12, and FKBP12-dependent cytotoxicity in cancer cells via the CellTrap effect. BRD4/FKBP12 ligand 2 can be used for the research of hematopoietic malignancy, multiple myeloma, prostate carcinoma, acute myeloid leukemia.
-
BRD3/BRD4-L ligand-2
0 ImagesCat. No.: HY-175924CAS No.: 3075063-28-1
-
QS-57
0 ImagesCat. No.: HY-169081QS-57 is a heterobifunctional targeted protein localization (TPL) agent. QS-57 binds to BRD4 via its JQ1 domain and covalently targets 14-3-3σ to form a ternary complex. QS-57 sequesters nuclear BRD4 in the cytoplasm, impairing the nuclear transcriptional regulatory function mediated by BRD4. QS-57 significantly reduces the nuclear BRD4 protein level and increases the cytoplasmic BRD4 protein abundance in cancer cells. QS-57 can be used for research on breast cancer and colorectal cancer.
-
CBP/p300/BRD4 ligand-1
0 ImagesCat. No.: HY-181759CAS No.: 3086024-48-5CBP/p300/BRD4 ligand-1 is a small-molecule inhibitor targeting CBP, p300, and BRD4. CBP/p300/BRD4 ligand-1 competitively binds to the functional domains of target proteins without disrupting key interactions. CBP/p300/BRD4 ligand-1 can be used for the construction of dual-target PROTAC degraders (HY-181758) in studies related to prostate cancer and other cancers.
-
BRD4 ligand 16
0 ImagesCat. No.: HY-184874CAS No.: 3032781-39-5BRD4 ligand 16 is a BRD4 ligand. BRD4 ligand 16 can serve as a ligand for the target protein in the synthesis of BRD4 PROTAC degraders, such as PROTAC BRD4 Degrader-17 (HY-143328). BRD4 ligand 16 is suitable for use in cancer research.
-
BRD4/FKBP12 ligand 1
0 ImagesCat. No.: HY-176477BRD4/FKBP12 ligand 1 is a heterobifunctional BRD4 and FKBP12 (Kd of 0.4 nM) ligand. BRD4/FKBP12 ligand 1 has positive cooperativity in BRD4 binding when pre-bound to FKBP12, and FKBP12-dependent cytotoxicity in cancer cells via the CellTrap effect. BRD4/FKBP12 ligand 1 can be used for the research of acute myeloid leukemia, multiple myeloma, prostate carcinoma.
-
FLT3/JAK2/BRD4 ligand-1
0 ImagesCat. No.: HY-175611CAS No.: 3067695-60-4
-
BRD4 ligand 15
0 ImagesCat. No.: HY-182371CAS No.: 3076613-24-3
-
BRD4 ligand 13
0 ImagesCat. No.: HY-178094CAS No.: 1101702-81-1BRD4 ligand 13 is a BRD4 ligand that can be used for the synthesis of PROTACs, such as Cath-L-dBET1 (HY-173257). BRD4 ligand 13 is a target protein ligand-conjugate that can be used for the synthesis of PROTACs, such as SJH1-51B (HY-162240).
-
BRD4 ligand 10
0 ImagesCat. No.: HY-185884CAS No.: 2086299-38-7BRD4 ligand 10 is a PROTAC target protein ligand. BRD4 ligand 10 can be used to synthesize PROTAC BRD4 Degrader-49 (HY-185854).
- 1
